Latest Conference Articles

July 30th 2022, 10:00am

International Congress on the Future of Breast Cancer West

Nicholas P. McAndrew, MD, MSCE, discusses considerations to take when examining the relationship between chemotherapy, ovarian function suppression, and treatment benefits experienced by patients with hormone receptor–positive, HER2-negative breast cancer.

July 29th 2022, 10:43pm

International Congress on the Future of Breast Cancer West

Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.

July 29th 2022, 9:21pm

International Lung Cancer Congress

Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.

July 29th 2022, 9:00pm

International Congress on the Future of Breast Cancer West

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

July 29th 2022, 9:00pm

International Congress on the Future of Breast Cancer West

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

July 29th 2022, 9:00pm

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

July 29th 2022, 8:53pm

International Lung Cancer Congress

PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.

July 29th 2022, 8:48pm

International Lung Cancer Congress

With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.

July 29th 2022, 5:15pm

International Lung Cancer Congress

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

July 29th 2022, 4:27pm

International Congress on the Future of Breast Cancer West

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

July 29th 2022, 3:37pm

International Lung Cancer Congress

Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.

July 28th 2022, 10:44pm

International Lung Cancer Congress

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.

July 28th 2022, 10:41pm

International Lung Cancer Congress

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

July 28th 2022, 10:23pm

Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.

July 28th 2022, 10:22pm

International Lung Cancer Congress

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.

July 28th 2022, 10:10pm

Thought minimal residual disease can serve as an indicator for poor outcomes for patients with non–small cell lung cancer, it is not necessarily a predictor of response to immunotherapy.

July 22nd 2022, 5:25pm

Pan Pacific Lymphoma Conference

Mutations in the p53 gene are associated with poor prognosis for patients with mantle cell lymphoma. Although modern regimens have improved outcomes, those treatments are associated with significant toxicity and, so far, have produced limited efficacy.

July 22nd 2022, 4:56pm

Pan Pacific Lymphoma Conference

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

July 22nd 2022, 4:55pm

Pan Pacific Lymphoma Conference

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.

July 22nd 2022, 4:41pm

Pan Pacific Lymphoma Conference

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.